免疫检查点抑制剂（ICIs）已经改善了晚期食管鳞状细胞癌（ESCC）患者的生存率。放疗是治疗食管癌的常见疗法之一。然而，联合放疗能否增加免疫治疗的疗效仍存在争议。放疗与免疫治疗的联合已被证实是可靠有效的肿瘤治疗方法，可以与免疫治疗相结合，实现更好的抗肿瘤效果。本综述旨在讨论联合放疗和免疫治疗治疗分期的ESCC的疗效和安全性，以及最佳放疗剂量和靶区，总结ESCC的临床试验。版权所有 © 2023. 由Elsevier B.V.出版。

Immune checkpoint inhibitors(ICIs) have improved the survival of advanced esophageal squamous cell carcinoma (ESCC) patients. Radiotherapy is one of the common therapies to treat esophageal cancer. However, whether combination radiation therapy can increase the efficacy of immunotherapy is still up for debate. Radiotherapy combined with immunotherapy has proven to be a reliable and effective treatment for tumors, and it can work in combination with immunotherapy to achieve better anti-tumor effects. This review aims to discuss the efficacy and safety of combining radiotherapy and immunotherapy to treat ESCC by stages as well as the optimum radiotherapy dose and target volume, with a summary of clinical trials in ESCC.Copyright © 2023. Published by Elsevier B.V.